We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.025 | -3.13% | 0.775 | 716,382 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.75 | 0.80 | 0.775 | 0.775 | 0.775 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 9k | -2.04M | -0.0154 | -0.50 | 1.06M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 09:40:42 | O | 23,000 | 0.795 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/12/2024 | 16:45 | UK RNS | ValiRx PLC Broker Offer Results & Director/PDMR Subscription |
| 10/12/2024 | 15:03 | UK RNS | ValiRx PLC Posting of Circular and Notice of General Meeting |
| 09/12/2024 | 07:00 | UK RNS | ValiRx PLC Conditional Fundraising & Launch of Broker Offer |
| 22/11/2024 | 07:00 | UK RNS | ValiRx PLC Inaphaea award of HEIF Funding and PhD sponsorship |
| 20/11/2024 | 18:09 | ALNC |  IN BRIEF: ValiRx extends Ambrose Healthcare exclusivity agreement |
| 20/11/2024 | 07:00 | UK RNS | ValiRx PLC Update on proposed sub-license of VAL401 |
| 19/11/2024 | 11:39 | ALNC | ValiRX adds to streak of deals with cancer cell test materials win |
| 19/11/2024 | 07:00 | UK RNS | ValiRx PLC Contract Award |
| 18/11/2024 | 12:21 | ALNC | IN BRIEF: ValiRx notes subsidiary's shipment of patient derived cells |
| 18/11/2024 | 07:00 | UK RNS | ValiRx PLC First Sale of New Product Line |
Valirx (VAL) Share Charts1 Year Valirx Chart |
|
1 Month Valirx Chart |
Intraday Valirx Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/12/2024 | 22:02 | VALIRX - A Significantly Undervalued Pharma | 10,734 |
| 12/12/2024 | 21:35 | RAINMAKER'S VALUE THREAD | 8,607 |
| 11/8/2024 | 10:16 | The dawn appears | - |
| 25/6/2024 | 15:03 | BITCOIN TRADING | 2 |
| 25/6/2024 | 10:19 | Valirx 24/07/2018 Post GM | 8,414 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 09:40:43 | 0.80 | 23,000 | 182.85 | O |
| 09:19:16 | 0.79 | 61,778 | 488.05 | O |
| 09:11:46 | 0.78 | 93,117 | 728.17 | O |
| 09:08:18 | 0.80 | 12,583 | 100.16 | O |
| 08:46:28 | 0.80 | 5,842 | 46.50 | O |
| Top Posts |
|---|
Posted at 13/12/2024 08:20 by Valirx Daily Update Valirx Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 0.80p.Valirx currently has 132,348,673 shares in issue. The market capitalisation of Valirx is £1,019,085. Valirx has a price to earnings ratio (PE ratio) of -0.50. This morning VAL shares opened at 0.78p |
Posted at 02/12/2024 01:10 by rainmaker Hi ST,Re multi baggers. In my long experience over the years, that in addition to the important factor of a very low base you mention, there has to be something or a combination of factors that "The Market" has missed,failed to appreciate, simply misundertood or don't have the prequisite skills or knowledge to recognise. Then there are quite a few market "blind spots" that I have witnessed over the years where Investors should but failed miserably to identity great opportunities in the early stages prior to a five/10 fold+ share price rally, sometimes in as little as six months to a year. Furthermore Investors consistently fail to fully appreciate the potential growth in earnings and multi bagger share price returns. As a diehard Stockmarket Value Investor I refuse to pay for growth but invest in Companies where I know there will be strong growth. If you look at this in the context of Cavendish Financial(CAV), they are currently trading on a price/sales ratio of 0.9(ie market cap divided by annual sales) yet the capital market sector trades at an average 3.3 times sales(you can check this at "SimplyWallStreet") so applying that average sector rating to CAV currently 9.50p, gives a share price of 35p, a 268% increase. However since I am confident in a large increase in sales at CAV, from a very low base, I expect this to be a conservative figure. AIMHO, DYOR as I have done mine. Regards |
Posted at 01/12/2024 10:10 by base7 Doesn’t Marks employment contract include holiday entitlement & surely it is up to us all as individuals to decide how to holiday & what to consume.I recollect that George was partial due a drop of 2 of red & perhaps you did too .My memory maybe fading but I also recollect that it was Suzie who replaced you ,not George -! Apparently she too enjoyed a drink .I appreciate that Val is rapidly running out of funds & if a raise isn’t possible it maybe forced into Admin & ,if so ,I am sure you & George as well as Suzie & Mark would then possibly be looking to acquire Val IP for peanuts .You should also recollect who was running Val when 2 dilutions took place at 125 for 1 shares + other dilutions with zero results . You really should accept responsibility for your actions rather making rather pathetic accusations regarding Mark in an attempt to destabilise an already unstable situation & you should be ashamed of yourself as many PIs have lost large amounts of money here & that is not without repercussions for those concerned |
Posted at 05/9/2024 11:47 by jasonpugh Potential downside and upside.Downside. They do a placing at 1p. 50% down. Upside. Val401 option agreement signed before dec 5th. (Look on Ambrose healthcare website for details regarding Val 401).and look at the valirx rns dated dec 5th 2023. Val 201. I know. We’ve been waiting ages. however with the value of euda and the fact the merger with Theormrx is still on indicates a positive. Clx001. This could be the rerate of the century. This alone worth a stretch Cash burn could surprise with additional income from lab and don’t forget mark Ecclestones is generally regarded as formidable at obtaining grants. In conclusion. Downside 1p (-50%) Upside. 401 10p 201. 20p Clx001. 20p These 3 alone would rerate to 50p. This is extremely conservative. (See Adam Hargreaves evaluation on clx001) So take your pick. Ps. Porky please don’t reply. As This is only advice for investors and those thinking of investing. DYOR |
Posted at 28/8/2024 08:19 by jasonpugh Email from Adam michael and cc Georgia Wilson from Ambrose healthcare regarding Val 401.“Dear Jason As stated in the previous email regarding Val 401 the rules on disclosure apply to valirx regarding what information they release regarding their intentions and the option agreement. All the information regarding Val401 is on the Ambrose healthcare website. Valirx is of course listed. You would need to raise the question with the Valirx team directly about their intention to disclose. Best regards Adam” Interesting to see what valirx will disclose considering Val 401 is mentioned on their website and the fact that according to the rns dec 5th Ambrose have the option which in my view is going to happen. My only worry is why are Valirx procrastinating? And before the disgruntled employee of Valirx porky tries to downplay this. Go onto their website to verify. Even email them. They are very accommodating. Dyor |
Posted at 15/8/2024 09:01 by porky9 Hi Jason,You are correct, in the filings at CH in respect of Valiseek Limited. in 2014 the return had 10,811 shares of which 6,000 belong to Valirx, 4,000 to Tangent and 811 to Suzy Dilly. The PSC at companies house meanwhile says VAL hold “more than 25% but not more than 50%” so it just looks like the PSC might need updating as they do own more than 50% ie 55%. I did think that VAL owned more of 401 than that but as you say they state 55% on the company website for some time which does tally with the 6,000 shares figure of 10,811 figure at CH. Company websites are not always updated, It also says on the VAL website that under AIM rule 26 that Monecor (London) Ltd hold 3.37% of the stock yet a quick search on companies house confirms that company went into liquidation sept 23 nearly a year ago. To be fair VAL might not have been updated that they no longer hold shares but it illustrates the point the website might not be up to date. I think you need to see what the new board put up as forward plans for this business, as I say can they get costs under control and a new raise supported to drive it forwards, it will be tough in this market. Good luck to you |
Posted at 15/8/2024 02:26 by porky9 @JasonPughI can feel your absolute desperation for a share price spike to get out before its either lights out at VAL or the discounted placing hits hard, i get it. But you really are clutching at straws regarding Ambrose, yes they have the potential rights to 401 via the LOI signed with Valiseek. (part owned by Valirx 75% and part owned by Tangent Reprofiling Limited, Tangent is now 100% owned by Peptcell Limited). But In December, Ambrose could either ditch the LOI with Valiseek all together, renegotiate terms for a new LOI or ask to extend the existing one but as as today they have not raised enough cash for extensive trials and IF they do, it wont involve paying VAL any of that cash upfront, its highly unlikely as they are skint members, any money they did manage to raise as a private company would need to go on trials. When they agreed the initial LOI they offered Valiseek some token shares in Ambrose if you remember, they are not cash rich. The proposed deal with Ambrose is milestone led on results so at absolute best i recon nil upfront and possibly something on trial success if it then resulted in a licensing deal with cash upfront depending on what deal Ambrose could subsequently secure but this really is years off. So can you not see that your excitement of digging up outdated documents and comments is total folly? Well before the end of the year if VAL have not been able to raise cash it will likely be lights out for them and if shares get suspended pending administration you could actually argue a case for Ambrose or any other party, maybe even Adam with his limited company or APTA even if so inclined, offering the liquidators a token fee for the 401 asset likewise any of the other assets 201, CLX etc - Any of them could do that because as it stands its a liability that needs investment to develop. However, @Jason, if you did any proper research you would realise that although Valiseek Ltd is currently majority owned by Valirx its directors are Gerry Desler (the accountant) Suzy Dilly and Gregory Staloff so in effect, if VAL did go into administration then Valiseek Limited could also offer the administrators a token amount for the shares that Valirx owns, in addition they could also offer a token for 201 and CLX if there is any long term worth in those also. So if i was Suzy, i would probably sit back wait for it to pop and hard ball acquisition of 401 using Valiseek Limited, the asset 401 based on Valiseek's recent accounts has an intangible asset value of £235k, in a liquidation/ fire sale of assets 5% is the going rate so i would offer the administrators £12k for the shares Valirx owns in Valiseek and any appointed IP firm would likely take it, unless a better offer came in. The directors of Valirx have a short timed window IMO to turn this around, slash the running costs and get a raise supported to save the assets. IF they cant then its a scramble over who might bid for what. IMO the ONLY asset worth bidding for in that situation is in fact CLX. I wouldn't take Inaphaea labs over if you gave it me for free, i see it as a cash guzzling liability. Be interesting how all this unfolds. |
Posted at 13/8/2024 18:48 by base7 Jason-I sold 200k Val shares on 23/9/20 & retain a substantial number - my only regret , clearly being that I did not sell the lot!I sincerely hope that your faith in what our new CEO posted is rewarded as I stand to benefit substantially-which clearly would be my preference.However, the pragmatist in me suggested 3 possible scenarios & I am sure there will be more. If you had conviction in our CEOs comments you would be investing heavily & volume would consequently be much higher than the generally paltry daily volume.If you are right our share price will indeed be multiples of 2.5p & my guess is that we will find out very soon. Sincerely hope you are right but our share price says not ! |
Posted at 31/7/2024 06:55 by jasonpugh Rns dated dec 5th 2023Para 3,4 “Under the option agreement Ambrose healthcare has a 12 month period of exclusivity under which it may exercise the option to execute a global exclusive license of valiseeks val 401 asset under pre agreed terms……& Now valirx owns a big chunk of valiseek. Now please look at the Ambrose healthcare website under the news item about appointments of a scientific advisory board. Now look at the details regarding what it says about Val 401. This was just a couple of months ago. With Ambrose having an option agreement which expires in dec. do you think now they will execute this? I think so. Imho. DYOR. |
Posted at 28/6/2024 12:04 by porky9 Jason - unless you hold shares in EUDA it doesn’t matter if it’s share price rises bigger than Elon Musks empire, why would they want a two bit, potless additional cash drain on their books that would be an immediate liability when they can use their share price advantage to acquire more assets that are revenue producing.Talk about punters being sold a lemon by the VAL board, bloody hell, sooner Adrian wakes up and cuts this nonsense relationship the better |
Posted at 05/4/2024 10:38 by porky9 @lucifier7OK for the purpose of entertainment please educate me as to why you think the business as it stands today is worth more than it’s £5m MCap? My reasoning why it isn’t: MCap was £2.25m in April 21 at its previous restructure yet back then was better positioned and had cash burn under £1.5m 201 is going nowhere, totally neglected and likely superseded, over 15 years old and needs reformulating and new patents, it’s handling a total disaster 301 same and off back of same tech and doing zero. 401 moved to another start up that is trying to get funding for itself to survive being a Phoenix business so little chance of any value there in next 12 months CLX - yes this has potential value I will put it at £1m top side. It needs at least another year dev on it and £400k more to try and position it. So Jam tomorrow for 2025 maybe but won’t be contributing to keep VAL alive short term Labs - what a bloody farce, zero paying customers, decision to buy a load of cell samples sitting in freezers from Imogen that couldn't make its business viable even with 32 staff at its height and the current BOD want to chuck more of your cash at it. I put lab assets at £500k top side if they could find a buyer. So that’s it, I calculate £1.5m of assets at best and a cash burn of £2.5m to feed a load of greedy directors to maintain lifestyles. As cash will likely run out July perhaps the BOD should award themselves a nice big bonus whilst they still have the cash. So please explain how you get a value to justify its current share price? I don’t see it. Even with a new BOD at a penny raise it’s a risk. It’s certainly in a worse place than it was in April 21. I put Share price should be in the region of 1.5p to 1.7p pre 1p Placing IMO |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
